Date on which the terms and conditions of the subsequent offering/repair offering were announced: 11 March 2025; Date of approval: Expected to be on or about 11 April 2025 by resolution of an ...

Reference is made to the stock exchange notice from IDEX Biometrics ASA ("IDEX" or the "Company") on 11 March 2025 regarding irrevocable undertakings from certain existing shareholders for a total ...

Reference is made to the stock exchange notice from IDEX Biometrics ASA ("IDEX" or the "Company") on 11 March 2025 regarding irrevocable undertakings from certain existing shareholders for a total ...

The Subsequent Offering will be carried out as set out in an offering prospectus (which must be approved by the Norwegian Financial Supervisory Authority) to be published prior to commencement of ...

The board of directors of the Company has resolved not to proceed with the Subsequent Offering. The background for the cancellation is that the Company's shares have traded at or below the ...

The board of directors of the Company has resolved not to proceed with the Subsequent Offering. The background for the cancellation is that the Company's shares have traded at or below the ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION ...

The subsequent offering period for the Offer, which commenced on January 22, 2018, expired as scheduled at 12:00 midnight, New York City time, on January 31, 2018. According to Novartis ...